// App-Quantinova.ai

518 : DNA methylation in serum as an independent marker of outcome and treatment response in TBCRC 005: A prospective study in metastatic breast cancer (MBC) patients.

Researchers

Presenter

  • Kala Visvanathan

Principal Investigators

  • Mary Jo Fackler

  • Zhe Zhang

  • Rita Nanda

  • Nancy U. Lin

  • Lisa A. Carey

  • James N. Ingle

  • Saraswati Sukumar

  • Lori J. Sokoll

  • Leslie Cope

  • Christopher Umbricht

  • David Euhus

  • John T. Carpenter

  • Anna Maria Storniolo

  • Antonio C. Wolff

  • Zoila Lopez-Bujanda

  • Stacie Jeter

Medical Centers

  • Johns Hopkins Kimmel Cancer Center and Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

  • The Johns Hopkins University, School of Medicine, Baltimore, MDDana-Farber Cancer Institute, Boston, MAJohns Hopkins, Baltimore, MD

  • University of Alabama at Birmingham, Birmingham, AL

  • The University of Chicago Medical Center, Chicago, IL

  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

  • UNC Chapel Hill, Chapel Hill, NC

  • Mayo Clinic, Rochester, MN

  • Johns Hopkins Kimmel Cancer Center, Baltimore, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Aldo-Keto Reductase Family 1 Member B

  • Circulating tumor cells

  • Ras Association Domain Family Member 1

  • DNA methylation

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved